Phase 2/3 RCT in 648 infants in India: adjuvanted dose-sparing IPV was non-inferior to full-dose IPV for seroconversion to poliovirus types 1-3 after three doses (type 1: 94.7% vs 92.8%), with a similar safety profile.
RCTn = 648
Kulkarni et al. Immunogenicity and safety of a dose-sparing inactivated poliovirus vaccine in infants in India: a phase 2/3, double-blind, randomised controlled trial